The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy. Click below to view current and past results.
- C-Suite Survey Underscores Digital Technology’s Growing Role in Clinical Trials
- 2020 Q1 Discussion Part 5 – Sales and Marketing Concepts, Political Pressures and Overarching Economic Effects
- 2020 Q1 Discussion Part 4 – In- and Out-Licensing Activities and CRO Outsourcing
- 2020 Q1 Discussion Part 3- Raising Capital and Mergers and Acquisitions
- 2020 Q1 Discussion Part 2- Impact of AI, Machine Learning, and New Technologies
- 2020 Q1 Discussion Part 1- Fundamentals of Running a Biopharmaceutical
- 2018 Q3 Results
- 2017 Q2 Results
- 2016 Q3/Q4 Results
- 2016 Q2 Results
- 2016 Q1 Results
- 2015 Q4 Results
- 2015 Q3 Results
The BCI is intended to be a forward-looking index designed to measure c-suite and executive leadership sentiment in the biopharma industry asking questions about their confidence levels concerning key issues. We look for the BCI to become a valuable and highly sought-after resource for its key insights across both key industry-related issues and business functions, including:
- Capital Markets
- Deal Landscape
- Mergers and Acquisitions
- Clinical Development
- Regulatory Affairs
- Commercialization
- Business Model and Workforce